BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 33051337)

  • 21. Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma.
    Srivastava A; Gupta A; Patidar S
    Clin Transl Oncol; 2021 Oct; 23(10):1967-1978. PubMed ID: 33840014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for ovarian cancer in the general population.
    Gentry-Maharaj A; Menon U
    Best Pract Res Clin Obstet Gynaecol; 2012 Apr; 26(2):243-56. PubMed ID: 22182415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
    Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
    Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study.
    Funston G; Hamilton W; Abel G; Crosbie EJ; Rous B; Walter FM
    PLoS Med; 2020 Oct; 17(10):e1003295. PubMed ID: 33112854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer.
    Wang B; Yu L; Yang GZ; Luo X; Huang L
    Asian Pac J Cancer Prev; 2015; 16(7):3003-7. PubMed ID: 25854397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
    Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
    [No Abstract]   [Full Text] [Related]  

  • 27. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
    Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
    J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
    Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on ovarian cancer screening.
    Munkarah A; Chatterjee M; Tainsky MA
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):22-6. PubMed ID: 17218847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
    Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Diagnostic Value of Transvaginal Sonograph (TVS), Color Doppler, and Serum Tumor Marker CA125, CEA, and AFP in Ovarian Cancer.
    Zhang F; Zhang ZL
    Cell Biochem Biophys; 2015 Jun; 72(2):353-7. PubMed ID: 25582421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
    Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
    J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.
    Drescher CW; Shah C; Thorpe J; O'Briant K; Anderson GL; Berg CD; Urban N; McIntosh MW
    J Clin Oncol; 2013 Jan; 31(3):387-92. PubMed ID: 23248253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application value of Doppler ultrasound combined with CA125 and CA19.9 in the early diagnosis of epithelial ovarian cancer.
    Cui Y; Shi S; Zhang S; Huang C; Li P; Han C
    J BUON; 2021; 26(5):1802-1808. PubMed ID: 34761586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Ã…kesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening.
    Drescher CW; Hawley S; Thorpe JD; Marticke S; McIntosh M; Gambhir SS; Urban N
    Cancer Prev Res (Phila); 2012 Aug; 5(8):1015-24. PubMed ID: 22750949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designing early detection programs for ovarian cancer.
    Urban N
    Ann Oncol; 2011 Dec; 22 Suppl 8(Suppl 8):viii6-viii18. PubMed ID: 22180403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention and early detection of ovarian cancer: mission impossible?
    Bast RC; Brewer M; Zou C; Hernandez MA; Daley M; Ozols R; Lu K; Lu Z; Badgwell D; Mills GB; Skates S; Zhang Z; Chan D; Lokshin A; Yu Y
    Recent Results Cancer Res; 2007; 174():91-100. PubMed ID: 17302189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.